Nearly 25 years after the discovery of pathogenic variants in MAPT (encoding the microtubule-associated protein tau) in familial frontotemporal dementia (FTD; [1, 2]; reviewed in [3]), there are still no effective therapeutics capable of halting or delaying tau-associated neurodegeneration [4, 5]. This evidence concerns the gene MAPT and frontotemporal dementia.